📰 Cov Phase News
Cov Phase News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Cov Phase. Real-time updates on events, politics, business and more.
April 25, 2023
Issuer: CureVac / Key word(s): Quarterly / Interim Statement CureVac Announces Financial Results for the Fourth Quarter and Full-Yea...
April 25, 2023
Investegate announcements from CureVac, CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update
April 25, 2023
Issuer: CureVac / Key word(s): Quarterly / Interim Statement25.04.2023 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update  In 2022, ongoing business transformation drive...
November 16, 2022
Issuer: CureVac / Key word(s): Quarterly / Interim Statement CureVac Announces Financial Results for the Third Quarter and First Nin...
November 16, 2022
Issuer: CureVac / Key word(s): Quarterly / Interim Statement16.11.2022 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update Delivering on broad second-generation vacc...
November 16, 2022
Investegate announcements from CureVac, CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update
November 16, 2022
Delivering on broad second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSKPhase 1 studies in influenza and COVID-19 on track to deliver clinical
August 18, 2022
Issuer: CureVac / Key word(s): Quarter Results18.08.2022 / 13:05 The issuer is solely responsible for the content of this announcement.CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update Delivering on broad 2022 second-generation vaccine development program...
August 18, 2022
Delivering on broad 2022 second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK; new candidates in COVID-19 and influenza enter clinical studiesPhase
August 18, 2022
18.08.2022 - Issuer: CureVac / Key word(s): Quarter Results CureVac Announces Financial Results for the Second Quarter and First Half of 2022 and Provides Business Update 18.08.2022 / 13:05 The issuer is solely responsible for the content of this ...